RIVAC-INC.
7.8.2019 11:02:06 CEST | Business Wire | Press release
RIVAC Inc. has announced the release of an iPhone App 'FrontShot' that enables real-time display and shooting of a straight frontal view of any plane, even if the camera is pointed from an oblique direction. Operation is simple, and you can see a straight frontal view of any plane, such as a document or wall, through the camera.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190807005001/en/
Official website: https://www.english.rivac.co.jp
[Background of FrontShot development]
There are times when you want to shoot a straight frontal view of an object such as a document, wall, poster, or time-table. In cases like this, it is convenient if you can just point your camera from an oblique direction, and see the straight frontal view. FrontShot was developed to make this possible. Even if you point your camera from an oblique direction, any sort of plane —documents, walls, etc.— can be viewed as a straight frontal image.
[Features]
Has three modes: horizontal plane, vertical plane, and slanted plane.
- Can handle any plane
The app can handle not only horizontal and vertical planes, but also slanted planes, and thus it is possible to see a straight frontal view of any plane. Naturally, it is also possible to see straight frontal views of ceilings. (Ceilings are regarded as horizontal planes.)
- Simple operation
Operation is extremely simple. For a horizontal plane, no special operation is necessary. Simply point the camera, and the straight frontal image will appear. For a vertical or slanted plane, the orientation of the plane must be designated (automatically or manually), but if the mode is set to automatic, a straight frontal image will appear just by pointing the camera, as with a horizontal plane. Operation is simple in manual mode too. Just point the camera in the direction of the plane, and press the button. A straight frontal image of the plane will appear.
*In the automated mode for vertical and slanted planes, the system calculates the direction of the plane by recognizing the horizontal and vertical lines which appear.
- Display in real-time
Processing is performed at high speed using our unique technology, and this makes it possible to display straight frontal images in real-time.
[Uses]
The app can be used for a variety purposes including: documents, posters, whiteboards, time-tables, buildings, signs, pictures, lettering and pictures drawn on the ground, and online sale items (clothes, books, CDs, other flat items).
[App information]
App name |
: |
FrontShot |
Device |
: |
iPhone (iOS9 or later) |
Category |
: |
Photo & Video |
Price |
: |
Check at the App Store. (A free trial is available. The product version can be purchased from the free version via in-app purchase.) |
| Released | : | August 5, 2019 |
iTunes URL |
: |
|
Official website |
: |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190807005001/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for futur
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 07:00:00 CET | Press release
SkyDefender is a multi-layer, multi-domain Integrated Air and Missile Defence system providing full protection against all types of air threats, on land, at sea and in space. SkyDefender integrates a network of advanced sensors and effectors with a versatile command and control (C2) system. With its open and modular architecture, it is fully compatible with existing air defence systems. Combining Thales’ expertise in cybersecurity and advanced artificial intelligence through cortAIx, Thales AI accelerator, SkyDefender enables operational superiority and proactive defence against cyberattacks and evolving threats. Thales is capable of delivering this critical protection globally from today. As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 07:00:00 CET | Press release
Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well as speciality care medicines in Japan, including a blockbuster drug. The agreement with Neupharma includes upfront and milestone payments of up to CHF 83.5 million as well as royalties of up to 20% on sales. The population of available patients eligible for corticorelin treatment associated with peritumoral brain edema is estimated at 60,000 in Japan and 500,000 worldwide. Global market potential is forecasted to exceed USD 1 billion annually. Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rig
Galderma Completes Successful Placement of EUR 500 Million Eurobond11.3.2026 06:55:00 CET | Press release
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%. The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange. Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction. Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings. Galderma is currently rated ‘BBB’ (stable outlook) by Fitc
Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 202510.3.2026 22:52:00 CET | Press release
- Sustainable Growth Driven by International Expansion - Significant Increase Across Key Metrics Estithmar Holding Q.P.S.C. has announced its financial results for the year ended 31 December 2025. The group reported a 54% increase in revenue to QAR 6.4 billion, compared with QAR 4.2 billion in 2024. Gross profit rose to QAR 2.1 billion, up from QAR 1 billion in 2024, representing growth of 111%. EBITDA reached QAR 1.5 billion, an increase of 102% year-on-year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310410214/en/ Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 2025 (Photo: AETOSWire) Net profit climbed 122% compared with 2024, reaching QAR 938 million. Earnings per share increased by 145% to QAR 0.264. The growth in net profit was primarily driven by higher revenues, particularly from the specialized contracting and healthcare sectors.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom